Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.54 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992184 | 1.00 | PRKCA (0.54) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL465982 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL15228719 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL14263115 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8394182 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8396305 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8394932 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL872500 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8394166 | 0.89 | LMNA (0.59) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL4458170 | 0.87 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632086-B2 | Methods and compositions for treating Raynaud's disease | NEXMED HOLDINGS, INC. (US) | 2020-04-28 | — | — | US | claimed |
| US-20180333377-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. (US) | 2018-11-22 | — | — | US | claimed |
| EP-2693877-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NexMed Holdings, Inc. (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012139033-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. (US) | 2012-10-11 | — | — | WO | claimed |
| EP-1028708-B1 | TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E1 DELIVERY | NEXMED HOLDINGS INC (US) | 2010-01-20 | — | — | EP | claimed |
| EP-1278495-A4 | TOPICAL COMPOSITIONS CONTAINING PROSTAGLANDIN E 1? | NEXMED HOLDINGS INC (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1255552-B1 | PROSTAGLANDIN COMPOSITIONS FOR THE TREATMENT FOR MALE ERECTILE DYSFUNCTION | NEXMED HOLDINGS INC (US) | 2005-03-09 | — | — | EP | claimed |
| EP-0746294-B1 | ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS | ODONTEX INC (US) | 2004-12-22 | — | — | EP | claimed |
| EP-1178833-B1 | TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E 1 DELIVERY | NEXMED HOLDINGS INC (US) | 2004-08-18 | — | — | EP | claimed |
| EP-1278495-A1 | TOPICAL COMPOSITIONS CONTAINING PROSTAGLANDIN E 1? | Nexmed Holdings, Inc. (US) | 2003-01-29 | — | — | EP | claimed |
| US-6414028-B1 | MIXTURE WITH SKIN PENETRATION INTENSIFIER, POLYSACCHARIDE GUM AND BUFFER | NEXMED HOLDINGS, INC. | 2002-07-02 | — | — | US | claimed |
| EP-1178833-A1 | TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E 1? DELIVERY | Nexmed Holdings, Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| US-6323241-B1 | PLACING IN THE FOSSA NAVICULARIS PROSATGLANDIN E1 AND A SKIN PENETRATION ENHANCER OF AMINOALKYLESTERS, GUM, LIPOPHILIC COMPOUND AND ACID BUFFER | NEXMED (HOLDINGS) INC. | 2001-11-27 | — | — | US | claimed |
| WO-2001074279-A1 | TOPICAL COMPOSITIONS CONTAINING PROSTAGLANDIN E¿1? | NEXMED HOLDINGS, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| WO-2001051053-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION | NEXMED HOLDINGS, INC. (US) | 2001-07-19 | — | — | WO | claimed |
| WO-2000069469-A1 | TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E1 DELIVERY | NEXMED HOLDINGS, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| US-6046244-A | COMPOSITION COMPRISING PROSTAGLANDIN E1, SKIN PENETRATION ENHANCER, POLYSACCHARIDE GUM, LIPOPHILIC COMPOUND, ACIDIC BUFFER SYSTEM | NEXMED HOLDINGS, INC. (US) | 2000-04-04 | — | — | US | claimed |
| EP-0746294-A4 | ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS | ODONTEX INC (US) | 1998-04-22 | — | — | EP | claimed |
| EP-0746294-A1 | ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS | ODONTEX, INC. (US) | 1996-12-11 | — | — | EP | claimed |
| WO-1995009590-A1 | ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS | ODONTEX, INC. (US) | 1995-04-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333377-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | PTGER1, PTGES, PTGS1 | PRKCA 2078/4885PRKCE 1775/4885PRKCQ 1649/4885 |
| US-10632086-B2 | Methods and compositions for treating Raynaud's disease | PTGER1, PTGES, PTGS1 | PRKCA 2078/4885PRKCE 1775/4885PRKCQ 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.